Openly accessible

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

Gromeier, M, Brown, MC, Zhang, G, Lin, X, Chen, Y, Wei, Z, Beaubier, N, Yan, H, He, Y, Desjardins, A, Herndon, JE, Varn, FS, Verhaak, RG, Zhao, J, Bolognesi, DP, Friedman, AH, Friedman, HS, McSherry, F, Muscat, AM, Lipp, ES, Nair, SK, Khasraw, Mustafa, Peters, KB, Randazzo, D, Sampson, JH, McLendon, RE, Bigner, DD and Ashley, David 2021, Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy, Nature Communications, vol. 12, no. 1, pp. 1-7, doi: 10.1038/s41467-020-20469-6.

Attached Files
Name Description MIMEType Size Downloads
muscat-verylowmutation-2021.pdf Published version application/pdf 1.50MB 17

Title Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Author(s) Gromeier, M
Brown, MC
Zhang, G
Lin, X
Chen, Y
Wei, Z
Beaubier, N
Yan, H
He, Y
Desjardins, A
Herndon, JE
Varn, FS
Verhaak, RG
Zhao, J
Bolognesi, DP
Friedman, AH
Friedman, HS
McSherry, F
Muscat, AMORCID iD for Muscat, AM orcid.org/0000-0003-1666-7961
Lipp, ES
Nair, SK
Khasraw, MustafaORCID iD for Khasraw, Mustafa orcid.org/0000-0003-3249-9849
Peters, KB
Randazzo, D
Sampson, JH
McLendon, RE
Bigner, DD
Ashley, David
Journal name Nature Communications
Volume number 12
Issue number 1
Start page 1
End page 7
Total pages 7
Publisher Nature Research
Place of publication Berlin, Germany
Publication date 2021-01-13
ISSN 2041-1723
Keyword(s) Cancer immunotherapy
CNS cancer
Immunoediting
Summary Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10–20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunotherapy intervention. We report that very low tumor mutation burden is associated with longer survival after recombinant polio virotherapy or after immune checkpoint blockade in recurrent glioblastoma patients. A relationship between tumor mutation burden and survival is not observed in cohorts of immunotherapy naïve newly diagnosed or recurrent glioblastoma patients. Transcriptomic analyses reveal an inverse relationship between tumor mutation burden and enrichment of inflammatory gene signatures in cohorts of recurrent, but not newly diagnosed glioblastoma tumors, implying that a relationship between tumor mutation burden and tumor-intrinsic inflammation evolves upon recurrence.
Language eng
DOI 10.1038/s41467-020-20469-6
Indigenous content off
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2021, The Author(s)
Free to Read? Yes
Use Rights Creative Commons Attribution licence
Persistent URL http://hdl.handle.net/10536/DRO/DU:30147317

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in TR Web of Science
Scopus Citation Count Cited 8 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 39 Abstract Views, 17 File Downloads  -  Detailed Statistics
Created: Mon, 18 Jan 2021, 07:20:48 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.